PIM1 and chronic myelogenous leukemia, BCR-ABL1 positive: These studies have shown that the use of dual inhibitors of CK2 and PIM-1 is beneficial for the reduction in cell proliferation and induction of apoptosis in cancer cell lines, i.e., cervical cancer (HeLa) and chronic myeloid leukemia (CML) [35,36].